Cholesterol IV is a treatment?
How crazy does it get? They have been telling us (quite wrongly) that cholesterol is a problem and causes heart attacks. Now, they are giving cholesterol IV, as a treatment!
This is how crazy “science” is. It flip flops remarkably every decade or so; usually not more than a quarter of a century, as I pointed out in my book “Virtual Medicine”.
Now brave pioneers have tried giving an IV infusion of “good” HDL cholesterol and found it rapidly removes cholesterol out of plaque-clogged arteries following a heart attack.
The study was small but the possibility is clear.
Of course cholesterol has NEVER been a problem. We need cholesterol, our liver makes far more of it than we could ever eat. Cholesterol is the basis many hormones, such as testosterone, estrogen, progesterone and cortisol.
The only health problem is oxidized cholesterol (hence the power of anti-oxidants to prevent heart disease). Once it goes rancid, cholesterol is pro-inflammatory and gets deposited in the walls of arteries, where it causes trouble.
But to blame cholesterol for a heart attack is like saying we should never use iron and steel, because sometimes it rusts. Duh!
The aim of this study was to try and reduce the high risk of a second heart attack in people who have had a heart attack. In the year after a heart attack, about 12% of people have a second heart attack or stroke.
Standard heart attack medications, such as aspirin and anti-clotting drugs, are aimed at preventing clotting. Of course they don’t address the real causes: diet, exercise, stress and other lifestyle issues!
Researchers infused a form of “good” cholesterol (HDL) and they found that cholesterol removal from cells rose 164%. There were no serious side effects.
In contrast, niacin, the vaunted “natural remedy” is only able to remove about 3% of plaque over the first 4 weeks.
So much for statins! And notice you are reading the death of a myth!
[The findings were presented here at the American Heart Association’s Scientific Sessions, Los Angeles, Nov. 3-7, 2012]